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A B S T R A C T
In Japan, transcatheter aortic valve implantation (TAVI) with Edwards-SAPIEN XT valve (Edwards
Lifesciences Inc., Irvine, CA, USA) started in October 2013. All institutions should undergo a training
period to perform TAVI independently. Balloon aortic valvuloplasty (BAV) as a bridge to TAVI during the
training period should be performed with caution to avoid severe aortic regurgitation (AR) because
bailout TAVI is not possible. We present a case in which BAV was successfully performed as a bridge to
TAVI during the training period. The patient was an 85-year-old man with medically uncontrollable
congestive heart failure due to severe aortic valve stenosis. The aortic valve area was 0.60 cm2with a left
ventricular ejection fraction of 20%. TAVI was considered a safe but high-risk strategy owing to the
unstable hemodynamic condition. We chose BAV as a bridge therapy to TAVI. The aortic annulus
diameter was 25.3 mm on computed tomography scans. We chose a 20-mm balloon catheter to avoid
BAV-induced AR. Transfemoral TAVI was performed successfully 16 days after BAV using a 26-mm
SAPIEN XT valve. The postoperative course was uneventful. The case demonstrated BAV as a bridge
therapy to TAVI can be safely and effectively performed during the training period.
<Learning objective: All institutions should undergo a training period to start transcatheter aortic valve
implantation (TAVI). Balloon aortic valvuloplasty (BAV) during the training period should be performed
with caution. The present case suggests that BAV as a bridge therapy to TAVI can be safely performed
during the training period. An accurate measurement of aortic annulus diameter and the use of an
undersized balloon catheter might reduce the risk of BAV-related aortic regurgitation.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Staged treatment is often conducted for patients with severe
aortic valve stenosis undergoing transcatheter aortic valve
implantation (TAVI). Several studies have demonstrated the
efﬁcacy of balloon aortic valvuloplasty (BAV) as a bridge therapy
to TAVI in high-risk patients [1,2]. Compared with the past, BAV is
currently conducted more frequently, with the introduction of* Corresponding author at: Department of Cardiovascular Medicine, Graduate
School of Medicine, Kyoto University 54, Shogoin Kawahara-cho, Sakyo-ku, Kyoto
606-8507, Japan. Tel.: +81 75 751 3198; fax: +81 75 751 3299.
E-mail address: naritatu@kuhp.kyoto-u.ac.jp (N. Saito).
http://dx.doi.org/10.1016/j.jccase.2015.05.006
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsTAVI [1,2]. One of the most serious complications after BAV is
uncontrollable aortic regurgitation (AR), which often requires
emergent surgical aortic valve replacement (SAVR) or TAVI [2–8].
In Japan, SAPIEN XT (Edwards Lifesciences Inc., Irvine, CA, USA) has
become commercially available at limited centers in Japan.
Therefore, TAVI is still in the introductory phase in most Japanese
institutions. Before commencing TAVI, all institutions are required
to undergo a training period. Special care is required when
conducting BAV as a bridge therapy during the training period
because bailout TAVI is not possible. Herein, we present a patient
with severe symptomatic aortic valve stenosis who was success-
fully treated with BAV and percutaneous coronary intervention
(PCI) to control congestive heart failure, followed by TAVI. The
procedure was conducted during the training period. reserved.
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An 85-year-old man with mild exertional dyspnea was referred
to our hospital for treatment of severe aortic stenosis. His brain
natriuretic peptide (BNP) level was 911 pg/mL. Transthoracic
echocardiography showed a severely calciﬁed tricuspid aortic
valve with a peak/mean transvalvular pressure gradient of 116/
70 mmHg, and valve area of 0.60 cm2. Left ventricular ejection
fraction was 50% and trivial mitral regurgitation was observed. The
patient had a history of PCI of the right and left circumﬂex coronary
arteries and received dual antiplatelet therapy with aspirin
(100 mg/day) and clopidogrel (75 mg/day). Coronary angiography
revealed a moderate to severe stenosis in the middle portion of the
right coronary artery (RCA). SAVR plus coronary artery bypass
grafting (CABG) or PCI plus TAVI was indicated for the patient. The
Society of Thoracic Surgeons (STS) risk score calculated for SAVR
plus CABG was 6.3%. However, the patient refused any invasive
treatments, and he was discharged from the hospital. Therefore,
medical therapy was continued in the outpatient clinic.
Three months later, the patient was readmitted to the hospital
because of acute exacerbation of congestive heart failure. Transtho-
racic echocardiography revealed that the left ventricular function
was signiﬁcantly reduced, with an ejection fraction of 20%. Mild
mitral regurgitation was also observed. Congestive heart failure
worsened despite medical treatment that included intravenous
administration of inotropes, diuretics, and vasodilators. The BNP
level was elevated to 5985 pg/dL, and chest radiography showed
severe pulmonary congestion, cardiomegaly, and bilateral pleural
effusions (Fig. 1A). The patient was deemed inoperable for SAVR plusFig. 1.
Changes on chest radiographs and in the brain natriuretic peptide (BNP) l
cardiomegaly, bilateral pleural effusions, and pulmonary congestion. (B) A che
observed, but cardiomegaly and pulmonary congestion are still present. (C) 
normal ﬁndings.
Fig. 2.
Fluoroscopic image during balloon aortic valvuloplasty (BAV) and simultaneou
BAV showing a mean pressure gradient of 51 mmHg and aortic valve area of
ventricular pacing. (C) The pressure tracing after BAV showing a mean pressCABG. The STS score was 12.5% at that time. TAVI was considered a
possible but high-risk strategy owing to the unstable hemodynamic
condition. We planned a staged procedure: ﬁrst, BAV and PCI to
stabilize the patient’s condition followed by TAVI under safer
conditions. This plan required approval by off-site proctors because
our institution was still in the proctoring period. All required data
were sent to the proctors, and the plan was approved after detailed
discussion.
After obtaining the approval of our institutional human ethics
committee and the written informed consent, BAV and PCI were
conducted under local anesthesia. Three introducer sheaths were
placed: a 12-F introducer sheath in the left femoral artery, a 5-F
introducer sheath in the right femoral artery, and a 7-F introducer
sheath in the right femoral vein. First, we conducted right heart
catheterization, which showed a mean right arterial pressure of
14 mmHg, mean pulmonary arterial pressure of 36 mmHg, and
mean pulmonary wedge pressure of 31 mmHg. Cardiac output,
determined by using the Fick method, was 2.35 L/min (cardiac
index = 1.49 L min1 m2). A 5-F Amplatz Left 1.0 diagnostic
catheter and a 0.035-inch straight guidewire were used to cross
the stenotic aortic valve. Simultaneous pressure tracing demon-
strated a mean pressure gradient of 51 mmHg across the aortic
valve, and the aortic valve area was 0.32 cm2, as calculated by
using the Gorlin formula (Fig. 2A). The aortic annulus diameter was
approximately 25 mm on computed tomography scans (Fig. 3). We
chose a 20-mm Maxi-LD balloon catheter (Cordis Corporation/
Johnson & Johnson, Bridgewater, NJ, USA) for BAV to avoid BAV-
induced AR. After placing a 0.035-inch extra-stiff guidewire in the
left ventricle, the balloon catheter was delivered retrogradely, andevel. (A) A chest radiograph before balloon aortic valvuloplasty (BAV) showing
st radiograph after BAV showing signs of improvement; no pleural effusion can be
The chest radiograph after transcatheter aortic valve implantation shows almost
s pressure tracings from the left ventricle and aorta. (A) The pressure tracing before
 0.32 cm2. (B) Balloon inﬂation with a 20-mm balloon catheter under rapid right
ure gradient of 14 mmHg and aortic valve area of 0.86 cm2.
Fig. 3.
Computed tomography scans. (A) Sinotubular junction diameter was 21.9 mm  25.0 mm. (B) Valsalva diameter was 29.4 mm  30.8 mm  31.3 mm. (C)
Annulus diameter was approximately 25 mm; the average diameter was 25.9 mm (diameter: 22.5 mm  29.2 mm), the diameter calculated from the perimeter
was 25.3 mm (perimeter: 79.5 mm), and the diameter calculated from the area was 24.9 mm (area: 488 mm2).
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heart rate of 200 bpm (Fig. 2B). Post-BAV simultaneous pressure
tracing showed that the mean pressure gradient decreased to
14 mmHg and the aortic valve area increased to 0.86 cm2 (Fig. 2C).
Transthoracic echocardiography showed that the AR remained
trivial. PCI for the RCA was subsequently performed. A 2.5-
mm  24-mm Promus premiere stent (Boston Scientiﬁc, Natick,
MA, USA) was implanted in the middle portion of the RCA. Both
BAV and PCI were completed successfully without any complica-
tions.
The patient’s symptoms and hemodynamic parameters im-
proved signiﬁcantly after BAV. In fact, the BNP level decreased, but
remained high, at 2867 pg/mL. Chest radiography showed
improvement of the congestive heart failure (Fig. 1B). Transtho-
racic echocardiography showed that the mean/peak transvalvular
pressure gradient decreased to 30/50 mmHg. The left ventricular
ejection fraction improved to 25% and mild mitral regurgitation
remained. Transfemoral TAVI was performed 16 days after BAV,
under supervision of the on-site proctor. An 18-Fr e-sheath was
inserted from the left femoral artery after surgical cut down, with
the patient under general anesthesia. The aortic valve was crossed
with a 5-F Amplatz Left 1.0 diagnostic catheter and a 0.035-inch
straight guidewire. Pre-dilatation was conducted with a 25-mm
Maxi LD balloon catheter (Cordis/Johnson & Jonson) under rapid
pacing at 200 bpm after placing a 0.035-inch extra-stiff guidewire
in the left ventricle. Then, a 26-mm SAPIEN XT valve was deployed
using 2 cc overﬁlled deployment balloon under rapid pacing at
200 bpm. Transesophageal echocardiography demonstrated that
the valve was implanted in the correct position with mild
perivalvular leakage. The 18-F e-sheath was retracted, and the
arteriotomy was closed. Fig. 4 shows the ﬂuoroscopic imagesFig. 4.
Fluoroscopic images during transcatheter aortic valve implantation. (A) An aor
regurgitation. (B) Implantation of a 26-mm SAPIEN XT valve under rapid right
intact coronary arteries.during TAVI. All procedures were successfully completed, and no
procedural complications occurred. The total procedure time from
skin to skin was 110 min, and the total amount of contrast media
was 90 mL.
Congestive heart failure improved remarkably after TAVI. The
BNP level decreased to 745 pg/mL, and chest radiography showed
no signs of congestive heart failure (Fig. 1C). Transthoracic
echocardiography performed 8 days after TAVI showed mild
paravalvular regurgitation, a peak/mean transvalvular pressure
gradient of 12/6 mmHg, and a valve area of 1.1 cm2. The left
ventricular ejection fraction was 36% with trivial mitral regurgita-
tion. The patient was discharged from the hospital 16 days after
TAVI.
Discussion
This is the ﬁrst case report demonstrating that BAV as a bridge
therapy to TAVI can be safely and effectively performed during the
proctoring period. BAV-induced severe AR was avoided with the
use of a smaller balloon catheter. The valve function and
hemodynamic status improved after BAV, which provided a better
patient condition for TAVI.
The indication of BAV has been limited in patients who are not
good candidates for SAVR because restenosis almost inevitably
occurs within a few months, and no clear survival advantage has
been demonstrated [6,9].
However, BAV is currently used more commonly as a bridge
therapy to TAVI. BAV provides better valve function and a more
stable hemodynamic condition for a short period. Within this period,
TAVI can be performed under safer conditions. Serious complica-
tions related to BAV include stroke, AR, cardiac tamponade,togram during pre-dilatation with a 25-mm balloon catheter showing trivial aortic
 ventricular pacing. (C) The ﬁnal aortogram showing mild aortic regurgitation and
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medically uncontrollable AR occurs after BAV, emergent surgical
valve replacement or TAVI is required to rescue the patient.
However, emergent TAVI is not an option during the proctoring
period. BAV during the proctoring period should be performed with
caution to avoid severe AR requiring surgical or percutaneous aortic
valve replacement. Severe AR after BAV is a rare but possible
complication. The frequency of BAV-induced severe AR varies from
0 to 6%, but is approximately 1% on average [2–9]. Several studies
recommended using smaller balloon catheter to avoid acute
complications after BAV [7,8,10]. An accurate measurement of
aortic annulus diameter with computed tomography and the use of
an undersized balloon catheter might reduce the risk of BAV-related
AR. In the present case, a 20-mm-diameter balloon catheter was
employed despite an annulus diameter of 25.0 mm, and the post-
BAV AR was trivial.
In summary, we present a case of severe aortic stenosis that
was successfully treated with BAV and staged TAVI. The results
suggest that BAV as a bridge therapy to TAVI can be safely
and effectively performed during the proctoring period, with
caution.
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